OncoCyte Corporation (NASDAQ: OCX) is -37.68% lower on its value in year-to-date trading and has touched a low of $0.24 and a high of $1.68 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OCX stock was last observed hovering at around $0.25 in the last trading session, with the day’s loss setting it -0.05% off its average median price target of $0.75 for the next 12 months. It is also 85.71% off the consensus price target high of $1.40 offered by 5 analysts, but current levels are 50.0% higher than the price target low of $0.40 for the same period.
Currently trading at $0.20, the stock is -46.12% and -49.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.21 million and changing -20.00% at the moment leaves the stock -70.27% off its SMA200. OCX registered -82.61% loss for a year compared to 6-month loss of -77.67%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a -55.56% gain in the last 1 month and extending the period to 3 months gives it a -52.61%, and is -45.95% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 23.43% over the week and 13.51% over the month.
OncoCyte Corporation (OCX) has around 110 employees, a market worth around $25.60M and $8.10M in sales. Distance from 52-week low is -17.29% and -88.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-95.70%).
OncoCyte Corporation (OCX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for OncoCyte Corporation (OCX) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.60, where 3 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
OncoCyte Corporation is expected to release its quarterly report on 05/16/2023.The EPS is expected to shrink by -57.70% this year
OncoCyte Corporation (OCX) Top Institutional Holders
The shares outstanding are 118.61M, and float is at 106.54M with Short Float at 0.94%.
OncoCyte Corporation (OCX) Insider Activity
A total of 7 insider transactions have happened at OncoCyte Corporation (OCX) in the last six months, with sales accounting for 2 and purchases happening 5 times. The most recent transaction is an insider purchase by Arno Andrew, the company’s Director. SEC filings show that Arno Andrew bought 250,000 shares of the company’s common stock on Dec 23 at a price of $0.35 per share for a total of $87875.0. Following the purchase, the insider now owns 0.53 million shares.
OncoCyte Corporation disclosed in a document filed with the SEC on Dec 23 that Gutfreund John Peter (Director) bought a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 23 and was made at $0.33 per share for $24728.0. Following the transaction, the insider now directly holds 75000.0 shares of the OCX stock.
Still, SEC filings show that on Dec 22, KINGSLEY ALFRED D (Director) acquired 25,000 shares at an average price of $0.28 for $7125.0. The insider now directly holds 439,111 shares of OncoCyte Corporation (OCX).
OncoCyte Corporation (OCX): Who are the competitors?
The company’s main competitors (and peers) include Omeros Corporation (OMER) that is -32.74% lower over the past 12 months.
